The corporate-backed genome editing technology developer Precision BioSciences, which was spun out of Duke University, floated in the middle of its range and is now valued at more than $780m.

Precision BioSciences, a US-based genome editing technology spinout of Duke University, raised more than $126m in its initial public offering last week. The offering consisted of 7.9 million shares issued on the Nasdaq Global Select Market priced at $16.00 each, in the middle of its $15 to $17 range, valuing the company at approximately $784m. Founded in 2006,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.